Isotopia Molecular Imaging

Company Overview

Snapshot

Founded in February 2007 by Eli Shalom, Isotopia Molecular Imaging operates with 51–200 employees. The company has secured $3.75 million across one funding round from Metrontario. In January 2025, Isotopia announced an agreement with Kinectrics for the supply of Gadolinium-160 to support the production of Terbium-161 for advanced radiotherapeutics.

Business overview

Isotopia Molecular Imaging is a global pharmaceutical company specializing in the development, production, and distribution of diagnostic and therapeutic radioactive isotopes, including advanced PET and SPECT radiotracers. Its core technology centers on radioisotopes like Lutetium-177, which shows promise in treating late-stage cancers such as metastatic prostate cancer and neuroendocrine tumors. The company serves the health tech and life sciences sectors, operating facilities that include an advanced nuclear pharmacy, a cyclotron facility, and an aseptic manufacturing plant that also provides contract manufacturing services.

Strategic signal

In January 2025, Isotopia Molecular Imaging entered into an agreement with Kinectrics for the supply of Gadolinium-160. This collaboration is crucial for supporting the production of Terbium-161, a key component for advanced radiotherapeutics. This strategic partnership signals Isotopia's continued focus on strengthening its supply chain for critical isotopes, which is vital for the ongoing development and commercialization of new cancer therapies and reinforces its position in the radiopharmaceutical market.

Company Intelligence Q&A

What was the most recent product launch for Isotopia Molecular Imaging?

In May 2025, Isotopia Molecular Imaging, in partnership with Cardirad, launched Isoprotrace® in Sweden and Denmark. This advanced Gallium-68 Gozetotide aims to expand access to advanced prostate cancer imaging.

What strategic supply agreement did Isotopia Molecular Imaging announce?

In January 2025, Isotopia Molecular Imaging and Kinectrics announced an agreement for the supply of Gadolinium-160 (Gd-160). This supply is intended to support the production of Terbium-161 (Tb-161) for advanced radiotherapeutics.

When did Isotopia Molecular Imaging launch Isoprotrace in Germany?

In March 2025, Isotopia Molecular Imaging officially launched Isoprotrace® in Germany, partnering with DSD Pharma to introduce the innovative radio-pharmaceutical.

What collaboration did Isotopia Molecular Imaging establish regarding Lutetium-177?

In September 2022, Clovis Oncology and Isotopia Molecular Imaging announced a Lutetium-177 Clinical Supply Agreement.

What production agreement did Isotopia Molecular Imaging make for n.c.a. Lu-177?

In September 2020, Isotopia Molecular Imaging and CPDC announced a production agreement for n.c.a. Lu-177.